Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Acino Holding AG

https://acino.swiss.com

Latest From Acino Holding AG

Focused China Local Strategy Remains Key Despite Country's Joining ICH – Executives

Top China executives from Pfizer, AstraZeneca, GSK share their views on growing in China amid lingering challenges despite regulatory progress.

China Regulation

Deal Watch: Merck Digging Into Epigenetics With Proteros Partnership

Merck could pay up to $167m to try a new epigenetic target, which would build on its existing HDAC inhibitor. Meanwhile, Celgene buys epigenetics-focused Acetylon, which will spin out new company Regenacy to work with its lead HDAC6 inhibitor outside of oncology.

Deals M & A

Curb Your Enthusiasm: Chinese Pharmas Going Global Hit Speed Bumps

Ambitious and confident Chinese pharmaceutical buyers have begun to enter a new brave world of foreign M&A. However, this scenario can be littered with internal challenges and increasingly external scrutiny, less solid pre-deal asset identification and poor post-deal execution, all of which can damage their barely gained credibility, creating hurdles for future deals.

Deals M & A

Luye Looks To Horizons Beyond Pharma, China

Dianbo Liu, chairman of the Hong Kong listed Luye Group, talks about the company’s ambitious plans to become a global top 100 pharmaceutical company through innovation, acquisitions and overseas expansion, and to broaden its activities well beyond selling medicines to meet changing patient needs and industry pressures.

Companies China
See All

Company Information

  • Industry
  • Contract Research, Toxicology Testing-CRO
  • Pharmaceuticals
    • Drug Delivery
      • Controlled Release
      • Transdermal
    • Generic Drugs
  • Services
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Acino Pharma Ltd.
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • Switzerland
  • Parent & Subsidiaries
  • Acino Holding AG
  • Senior Management
  • Peter Burema, CEO
    Martin Gertsch, CFO
    Jean-Daniel Bonny, PhD, Head, R&D
    Ruud van Anraat, Chief Commercial Officer
  • Contact Info
  • Acino Holding AG
    Phone: 61 338 60 00
    Dornacherstrasse 114
    Aesch, CH-4147
    Switzerland
Advertisement
Advertisement
UsernamePublicRestriction

Register